Table 1.
Patient characteristics at pretreatment of third-generation EGFR TKIs.
| Variables | N | % |
|---|---|---|
| Sex | ||
| Male | 26 | 32.1 |
| Female | 55 | 67.9 |
| Age | ||
| Median (range) | 64 (36–84) | |
| ≤60 | 32 | 39.5 |
| >60 | 49 | 60.5 |
| Histology | ||
| Adenocarcinoma | 79 | 97.5 |
| Squamous adenocarcinoma | 1 | 1.2 |
| Non-small cell lung cancer NOS | 1 | 1.2 |
| Smoking status | ||
| Non-smoking | 65 | 80.2 |
| Smoking | 16 | 19.8 |
| Clinical Staging | ||
| IIIB | 4 | 4.9 |
| IV | 77 | 95.1 |
| Central and nervous system metastasis | ||
| Yes | 27 | 33.3 |
| No | 54 | 66.7 |
| Treatment line | ||
| Second line | 57 | 70.4 |
| Third line | 15 | 18.5 |
| Beyond third line | 9 | 11.1 |